Table 1_High-efficacy serum biomarkers PCSK9 and LCAT predict cognitive impairment in Park

75 Parkinson's disease patients and 35 healthy controls underwent cognitive assessments and serum protein quantification. The study, authored by Mingyu Su and last updated in April 2026, measured six candidate proteins (INPP5D, FLNA, ICAM-1, PCSK9, JAK1, LCAT) via ELISA to identify biomarkers for cognitive impairment.

Use Cases

• Train binary classification models to distinguish PD patients with cognitive impairment from those without, based on serum biomarker levels.
• Perform multivariate regression analysis to explore relationships between specific proteins (e.g., PCSK9, LCAT) and cognitive assessment scores (MoCA, MMSE).
• Conduct pathway analysis to investigate the roles of focal adhesion and JAK-STAT signaling in Parkinson's disease pathology.
• Validate the diagnostic potential of the identified biomarkers using receiver operating characteristic (ROC) analysis.

Strengths

• Includes data from 110 total participants (75 PD patients, 35 controls), providing a defined cohort size.
• Quantifies six specific serum proteins (INPP5D, FLNA, ICAM-1, PCSK9, JAK1, LCAT) linked to neuroinflammation and lipid metabolism.
• Correlates biomarker levels with three standardized cognitive assessments (MoCA, MMSE, CDR).

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is small (291.5 KB), indicating limited scope and sample size.
• Data may reflect bias inherent to the specific retrospective, cross-sectional study design.

Provenance

Source

figshare, author Mingyu Su

Collection Method

Retrospective, cross-sectional study using ELISA quantification on an independent cohort.

Time Range

null

Freshness

Last updated 2026-04-15 04:36:55; freshness should be verified.

Geography

null